ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of infectious diseases. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate other early druggable properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.
ABAC Therapeutics shall extensively apply PasNas Technology Platform in close collaboration with a network of partners with expertise in chemical libraries construction (lead-like small molecules and natural products), in vitro and in vivo pharmacology and pharmacokinetics, medicinal chemistry and clinical development.
PasNas, the ABAC Therapeutics‘
PasNas is the drug discovery platform engineered and exploited by ABAC Therapeutics. It is a highly scalable and multiplex platform designed to reduce anti-infective drug attrition rates, based on management of technical risk and cut development costs. Ensuring that compounds with a better balance of weighted properties are prioritized and progressed at each stage-gate decision.
The PasNas platform has been validated and shows remarkable results. The successful application of the PasNas algorithm has allowed ABAC Therapeutics to discover new active compounds against some of the most clinically relevant Gram-negative and Gram-positive bacteria, both due to their incidence and the number of deaths they cause; specifically, molecules with pathogen-specific activity against Acinetobacter baumannii, Streptococcus pneumoniae and Staphylococcus aureus.